

1 Health-Related Quality of Life of Adults with Cutaneous Leishmaniasis at ALERT Hospital, Addis Ababa,  
2 Ethiopia

3  
4 Shimelis Doni<sup>1</sup>, Kidist Yeneneh<sup>2</sup>, Yohannes Hailemichael<sup>3</sup>, Mikyas Gebremichael<sup>3</sup>, Sophie Skarbek<sup>4</sup>,  
5 Samuel Ayele<sup>3</sup>, Abay Woday<sup>3</sup>, Saba Lambert<sup>1, 5</sup>, Stephen L. Walker<sup>5</sup>, Endalamaw Gadisa<sup>3</sup>

6  
7 **Affiliations:**

8 <sup>1</sup>ALERT Hospital, Addis Ababa, Ethiopia

9 <sup>2</sup>Addis Ababa University, Addis Ababa, Ethiopia;

10 <sup>3</sup>Armauer Hansen Research Institute, NTD and Malaria Research Directorate, Addis Ababa, Ethiopia

11 <sup>4</sup> Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

12 <sup>5</sup>Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London,  
13 United Kingdom

14

15 **Corresponding author:** Shimelis Doni

16 **Email:** [shimelis321@gmail.com](mailto:shimelis321@gmail.com)

17

18

19 **Abstract**

20 **Background:** Cutaneous leishmaniasis (CL) is a growing public health threat in Ethiopia. *Leishmania*  
21 *aethiopica* is the predominant causative organism. Affected individuals develop chronic skin lesions on  
22 exposed parts of the body, mostly on the face, which are disfiguring and cause scarring. The effects of CL  
23 on the health-related quality of life (HRQoL) of affected individuals has not been formally assessed in  
24 Ethiopia.

25 **Objective:** To assess HRQoL in adults with active CL at ALERT Hospital, Addis Ababa, Ethiopia.

26 **Methods:** A cross-sectional study was done using the Amharic version of the Dermatology Life Quality  
27 Index (DLQI). Trained health staff administered the DLQI.

28 **Results:** Three hundred and two adults with active CL participated and all of them exhibited a reduced  
29 HRQoL. The median DLQI score was 10 (IQR 8). Almost half of the participants reported very poor  
30 HRQoL, 36.4% and 11.3% fell within the very large and extremely large effect categories respectively.  
31 DLQI scores were higher (median 18) in patients diagnosed with diffuse cutaneous leishmaniasis (DCL)  
32 compared to those with localized cutaneous leishmaniasis (LCL). The DLQI domain of 'work and school'  
33 was the most affected, scoring 73.3% and 66.6% of total possible core for female and male respectively,  
34 followed by that of 'symptom and feeling' (at 50.0% and 56.6% for female and male respectively). Men  
35 were more affected than women in the domains of 'leisure' (P=0.002) and 'personal relationships'  
36 (P=0.001). In the multivariate ordinal logistic regression site of lesion, clinical phenotype and age  
37 remained associated with significantly poor HRQoL.

38 **Conclusion:** The HRQoL impairment in people affected by CL is significant. This warrants improved care  
39 and treatment in Ethiopia, counseling on the nature of CL, therapeutic options as well as clinical  
40 outcomes and complications. Importantly, patient-reported outcome measures including the DLQI  
41 should be used to assess treatment efficacy patient care algorithms.

42

### 43 **Plain Language Summary**

44 Cutaneous leishmaniasis (CL) is an important public health problem in Ethiopia with an estimated  
45 incidence up to 50,000 cases per year. CL is predominately due to *Leishmania aethiopica*. *The*  
46 *transmission* is zoonotic by *Phlebotomus longipes* and *Ph. pedifer*, and hyraxes being the incriminated  
47 reservoir hosts. The lesion is chronic on the exposed part of the body, commonly on the face. Three  
48 main clinical phenotypes are recognized; localized (LCL), mucocutaneous (MCL), and diffuse CL (DCL)  
49 cutaneous leishmaniasis. The permanent damage and altered anatomy of the skin, nose, eyelids, ears  
50 and lips due to scarring is often associated with stigma.

51 This study aimed to assess the health-related quality of life (HRQoL) using the Amharic version of the  
52 Dermatology Life Quality Index (DLQI) in adults diagnosed with active CL. Our results show that the  
53 impact on HRQoL associated with CL is large. There was no significant difference between men and  
54 women, and urban and rural dwellers. Participants with DCL, the more extensive form of CL, had lower  
55 HRQoL compared to those with other forms. Those with lesions on their head and neck regions and  
56 younger than 50 year (20 to 49 years age group) had significantly low HRQoL ( $P<0.05$ ).

57 The reduced HRQoL associated with CL in Ethiopia requires warrants improved, counseling on the nature  
58 of CL, therapeutic options as well as clinical outcomes and complications. Importantly, patient-reported  
59 outcome measures including the DLQI should be used to assess the efficacy of treatments and patient  
60 care algorithms.

61

62

63

64

## 65 **Introduction**

66 The leishmaniases are neglected tropical diseases caused by an intracellular protozoan of the genus  
67 *Leishmania* transmitted by the bite of infected female phlebotomine sandflies. Cutaneous leishmaniasis  
68 (CL) is the most common form of leishmaniasis with an estimated million new cases per year globally  
69 [1]. CL, caused by *Leishmania aethiopica* (*L. aethiopica*), is a major public health problem in Ethiopia with  
70 over 29 million people estimated to be at risk and up to 50000 new cases per year [2]. Affected  
71 individuals develop chronic, granulomatous cutaneous lesions on exposed parts of the body,  
72 predominantly the face. Lesions heal with scarring [3-5]. Children and young adults are the most  
73 affected [5-7]. The clinical phenotypes of CL due to *L. aethiopica* are localized (LCL), mucocutaneous  
74 (MCL) and diffuse (DCL) [8, 9]. MCL and DCL present significant therapeutic challenges.

75 CL has a severe psychosocial and economic impact, which contributes to perpetuating poverty. CL is  
76 associated with reduced health-related quality of life (HRQoL) of affected individuals due to the  
77 appearance of active skin lesions or the permanent scarring on exposed body sites [10, 11]. HRQoL  
78 encompasses physical activity, psychological well-being, degree of independence and social  
79 relationships, all of which are affected by skin disease [12]. Studies in other settings have shown  
80 affected individuals with CL have reduced quality of life. Boukthir et al., in a Tunisian study reported the  
81 impact of CL that ranged from scar related stigma to suicidal thoughts from fear of being handicapped  
82 and stress caused by close relatives [10]. Khatami et al. documented feelings of sadness, guilt, anxiety,  
83 stigma and exclusion through indepth interviews of 12 Iranian individuals with CL [11]. CL is associated  
84 with a negative impact on personal relationships and self-esteem resulting in anxiety and depression.  
85 Bennis et al., highlighted that CL could adversely affect life choices such as marriageability in endemic  
86 communities [13].

87 The Dermatology Life Quality Index (DLQI) has been used to assess the HRQoL of individuals with CL in  
88 Iran [14], Brazil [15] and the United Kingdom [16]. The proportion of individuals with a moderate or  
89 greater impact of their HRQoL ranged from 42.7-70%. There are no studies reporting data on HRQoL of  
90 individuals with CL in Ethiopia. We wished to assess the HRQoL using the DLQI in a referral hospital  
91 setting in Ethiopia.

## 92 **Methods**

### 93 **Study setting**

94 This work was done at the dermatology department of ALERT Hospital, Addis Ababa, Ethiopia

### 95 **Study population and data collection**

96 A cross-sectional study was performed between December 2018 and December 2021. Individuals aged  
97 18 years or older diagnosed with active CL (confirmed by microscopy and/or culture) who gave written  
98 informed consent were enrolled. The treating health care professionals classified participants as having  
99 LCL, MCL or DCL. Demographic and clinical data including location of lesions were recorded on a data  
100 collection form. The sites of skin lesions were categorised into regions as being on the head and neck or  
101 the torso and/or limbs or both regions. The head and neck skin lesions were further categorised into  
102 those affecting the face (not the lips or nose), lips or nose.

103 The validated Amharic version of the DLQI [17] was completed for each participant by a trained  
104 interviewer. The DLQI is a 10-item questionnaire addressing six aspects of life (domains); symptoms and  
105 feelings (Questions 1 and 2), daily activities (Questions 3 and 4), leisure (Questions 5 and 6), work and  
106 school (Question 7), personal relationships (Questions 8 and 9), and treatment (Question 10). The scores  
107 to each of the 10 items add up giving a total score ranging from 0 to 30. Individuals rate the impact of  
108 their dermatological condition in the past week as “not at all, scored 0”, “a little, scored 1”, “a lot,  
109 scored 2”, “very much, scored 3”, “not relevant, scored 0” or Question 7, ‘prevented work or studying’  
110 scored 3”. The HRQoL impact is interpreted using the total DLQI score as 0 – 1 no effect at all, 2 – 5 small  
111 effect, 6 – 10 moderate effect, 11 – 20 very large effect and 21 – 30 extremely large effect. The scores  
112 for each domain are expressed as a percentage of the total possible score for the domain. A higher DLQI  
113 scores means greater impairment on the patient’s health related quality of life (HRQoL).

#### 114 **Data management and analysis**

115 Data were checked for completeness and double entered into *EpiData* (version 3.1, *EpiData* Association,  
116 Odense, Denmark), exported and analyzed using *Stata* (version 17.0, *Stata* Corporation, College Station,  
117 TX, USA). A comparison of scores between two groups was made using the Mann–Whitney U inspected  
118 rank test, and for three or more groups the Kruskal–Wallis H test. Adjusted multivariable ordinal logistic  
119 regression analysis was performed to identify the independent predictors of effect of CL on HRQoL. P-  
120 values less than 0.05 were considered statistically significant.

#### 121 **Ethical consideration**

122 This study was reviewed and approved by AHRI/ALERT Ethics Review Committee (protocol number:  
123 PO/48/18). The participant information sheet and consent form were available in Amharic. Written  
124 informed consent was sought from all participants.

#### 125 **Results**

##### 126 **Characteristics of the participants**

127 Three hundred and two individuals diagnosed with active CL were recruited. The median age of  
128 participants was 29 years (IQR 21; 45), 56.0% male (169/302) and 66.6% urban dwellers (201/302). The  
129 body region most affected was the head and neck in 270 (89.4%), of which involve the nose in 151  
130 (50%), other sites on the face in 122 (40.4%), and the lips in 35 (11.6%). The proportion of clinical  
131 phenotypes were 62.6% LCL (189/302), 34.4% MCL (104/302), and 3.6% DCL (9/302) (Table 1).

132

133 **Table 1:** Sociodemographic, disease characteristics and Dermatology Life Quality Index (DLQI) scores of  
 134 participants

| Variables                   | Number (%) | DLQI Score |      |
|-----------------------------|------------|------------|------|
|                             |            | Median     | IQR  |
| <b>Age (years)</b>          |            |            |      |
| 18-19                       | 46 (15.2)  | 9.5        | 10.0 |
| 20-29                       | 106 (35.1) | 11         | 8.0  |
| 30-39                       | 46 (15.2)  | 14         | 9.0  |
| 40-49                       | 42 (13.9)  | 11         | 9.0  |
| ≥50                         | 62 (20.5)  | 8          | 5.0  |
| <b>Sex</b>                  |            |            |      |
| Male                        | 169 (56.0) | 11         | 9.0  |
| Female                      | 133 (44.0) | 10         | 8.0  |
| <b>Residence</b>            |            |            |      |
| Urban                       | 201(66.6)  | 10         | 8.0  |
| Rural                       | 101 (33.4) | 11         | 10.0 |
| <b>Body region affected</b> |            |            |      |
| Head and neck only          | 270 (89.4) | 10         | 8.0  |
| Trunk and /or limbs only    | 15 (5.0)   | 8          | 6.0  |
| Multiple body regions       | 17 (5.6)   | 11         | 11.0 |
| <b>Clinical phenotype</b>   |            |            |      |
| LCL                         | 189 (62.6) | 9          | 8.0  |
| MCL                         | 104 (34.4) | 11         | 9.5  |
| DCL                         | 9 (3.60)   | 18         | 11.0 |

135  
 136 In terms of participants' sex and clinical phenotype of CL, the males accounted for 55.5% (104/189),  
 137 55.77% (58/104) and 77.78% (7/9) of the LCL, MCL and DCL cases respectively (Table2).

138  
 139


140 **Table 2.** Male and female participants with clinical phenotype of cutaneous leishmaniasis

| Sex of participants | Clinical phenotype (n, %) |            |           |
|---------------------|---------------------------|------------|-----------|
|                     | LCL                       | MCL        | DCL       |
| Male                | 104 (55.03)               | 58 (55.77) | 7 (77.78) |
| Female              | 85 (44.97)                | 46 (44.23) | 2 (22.22) |
| Total               | 189 (100)                 | 104 (100)  | 9 (100)   |

141

142 **DLQI scores of participants**

143 The overall median DLQI score for the study participants was 10 (IQR 8). The range of DLQI scores was 2  
144 to 29. Median DLQI scores were higher in participants diagnosed with DCL (median 18) compared to  
145 participants with MCL (median 11) and LCL (median 9) (Table 1 and Figure 1). Similarly, participants in  
146 the 30-39 year age group had higher DLQI scores (median 14; IQR 9).



147

148 **Figure 1:** DLQI score associated with clinical phenotype of cutaneous leishmaniasis



149 **Size of HRQoL effect associated with active cutaneous leishmaniasis**

150 The size of the HRQoL effect of active CL as measured by DLQI score ranged from small effect to  
 151 extremely large effect (Table 3). Almost half of the participants reported very poor HRQoL, 36.4% and  
 152 11.3% fell within the very large and extremely large effect categories respectively. In addition, 39.4% of  
 153 the participants experienced a moderate effect. Exceptionally, all the nine individuals with DCL had a  
 154 DLQI score of 10 or more (Figure 1).

155 **Table 3: The size of effect on HRQoL associated with clinical phenotype of cutaneous leishmaniasis**

| HRQoL effect    | Clinical phenotype N (%) |           |          | Total N (%) |
|-----------------|--------------------------|-----------|----------|-------------|
|                 | LCL                      | MCL       | DCL      |             |
| Small           | 25 (13.2)                | 14 (13.5) | 0 (0)    | 39 (12.9)   |
| Moderate        | 85 (45.0)                | 33 (31.7) | 1 (11.1) | 119 (39.4)  |
| Very large      | 65 (34.4)                | 41 (39.4) | 4 (44.4) | 110 (36.4)  |
| Extremely large | 14 (7.4)                 | 16 (15.4) | 4 (44.4) | 34 (11.3)   |

156 **DLQI domains**

157 The percentage of domain scores were calculated from the total possible score. The percentage and the  
 158 medians/ Interquartile ranges for each of the six domains is shown in Table 4. The ‘work and school’  
 159 domain had a high (73.3% and 66.6% for females and males respectively) total possible scores whereas  
 160 the ‘personal relationships’ domain had low (16.6% and 25.0%, for females and males respectively). The  
 161 HRQoL impairment was more pronounced in males compared to females in the ‘leisure’ (P=0.002) and  
 162 ‘personal relationships’ (p= 0.001) DLQI domains.

163 **Table 4. Percentage of total possible domain score and median/ Interquartile range of DLQI domains**  
 164 **scores by sex of participants**

| DLQI domain                   | Percentage of possible score (Median, IQR) |                 | Rank Test | P value      |
|-------------------------------|--|-----------------|-----------|--------------|
|                               | Female (n=133)                             | Male (n=169)    |           |              |
| Symptoms and feelings (Q1,2)  | 50.0 (3 2 ;4)                              | 56.6 (3, 2; 5)  | Z 1.76    | 0.080        |
| Daily activities (Q3,4)       | 33.3 (2, 0;3)                              | 35.0 (2., 0;3-) | Z=0.057   | 0.954        |
| Leisure (Q5,6)                | 23.3 (1, 0;2)                              | 35.0 (2, 0;-3)  | Z=3.079   | <b>0.002</b> |
| Work and school (Q7)          | 73.3 (3, 1;3)                              | 66.6 (3, 1;3)   | Z=-1.404  | 0.160        |
| Personal relationships (Q8,9) | 16.6 (0, 0;2)                              | 25.0 (1, 0;3)   | Z=3.191   | <b>0.001</b> |

|                 |               |              |         |       |
|-----------------|---------------|--------------|---------|-------|
| Treatment (Q10) | 30.0 (1, 0;1) | 33.3 (1 0;2) | Z=0.424 | 0.671 |
|-----------------|---------------|--------------|---------|-------|

165

166 **Multivariate ordinal logistic regression**

167 In the multivariate, clinical phenotype of CL, age of participants and the affected body region remain  
168 significantly associated with DLQI scores (Table 5). The odds of having low HRQoL was eight times higher  
169 in DCL cases (P=0.003) compared to those with LCL. Younger, 20 to 49 years, age groups and those  
170 having their head and face region affected had higher odds of having very poor HRQoL compared to  
171 those in 50 years and above, and those that have lesions on their Trunk and/or limbs. There was no  
172 significant difference in DLQI scores between male and female participants (P=0.260) or rural and urban  
173 dwellers (P=0.354).

174 **Table 5:** Multivariate ordinal logistic regression of DLQI score with sociodemographic and disease  
175 characteristic participants

176

177

178

| Variable                  | Median(IQR) | COR(95%CI)    | AOR(95% CI)   | P-Value (AOR)    |
|---------------------------|-------------|---------------|---------------|------------------|
| <b>Age in years</b>       |             |               |               |                  |
| 18-19                     | 9.5(10)     | 1.9(1.0,3.7)  | 1.8(0.9,3.5)  | 0.082            |
| 20-29                     | 11(8)       | 2.2(1.3,3.8)  | 2.1(1.2,3.8)  | <b>0.007</b>     |
| 30-39                     | 14(9)       | 3.7(1.9,7.4)  | 3.6(1.8,7.3)  | <b>&lt;0.001</b> |
| 40-49                     | 11(9)       | 2.7(1.4,5.3)  | 2.7(1.3,5.3)  | <b>0.004</b>     |
| 50 and above              | 8(5)        | 1             | 1             |                  |
| <b>Sex</b>                |             |               |               |                  |
| Male                      | 11(9)       | 1.4(0.9,2.2)  | 1.2(0.8,1.9)  | 0.260            |
| Female                    | 10(8)       | 1             | 1             |                  |
| <b>Residence</b>          |             |               |               |                  |
| Urban                     | 10(8)       | 0.7(0.5,1.1)  | 0.8(0.5,1.2)  | 0.354            |
| Rural                     | 11(10)      | 1             | 1             |                  |
| <b>Body site affected</b> |             |               |               |                  |
| Multiple body parts       | 11(11)      | 4.0(1.2,13.6) | 2.2(0.6,7.7)  | 0.195            |
| Head and neck             | 10(8)       | 2.0(0.8,4.9)  | 3.2(1.2,8.4)  | <b>0.018</b>     |
| Trunk and/or limbs        | 8(6)        | 1             | 1             |                  |
| <b>Clinical phenotype</b> |             |               |               |                  |
| LCL                       | 9(8)        | 1             | 1             |                  |
| MCL                       | 11(9)       | 1.4(0.9,2.1)  | 1.3(0.8,2.0)  | 0.162            |
| DCL                       | 18(11)      | 5.7(1.7,18.4) | 8.0(2.0,31.5) | <b>0.003</b>     |

179

180 **Discussion:**

181 Skin diseases exert a considerable impact on social relationships, psychological status and on the daily  
 182 routine of patients. Cutaneous leishmaniasis, caused mainly by *Leishmania aethiopica*, is (re)emerging  
 183 public health challenge in Ethiopia. The disease causes severe disfigurement, because of either  
 184 destruction of and/or formation of lifelong scars on aesthetically important body parts [8].

185 The concept of HRQoL encompasses physical activity, psychological well-being, the patient's degree of  
 186 independence and his/her social relationships. Various studies showed the impact of CL in HRQoL of

187 affected individuals [14, 15, 18]. In this article, we presented the effect of CL on patients' HRQoL, as  
188 measured by the DLQI, at ALERT Hospital, in Ethiopia.

189 In this study the first of its kind involving large number of participants, the median DLQI score was 10  
190 (IQR 8). All participants with active CL experienced an effect on their HRQoL, which ranged from small  
191 effect to extremely large effect. Almost half of the participants reported very poor HRQoL, 36.4% and  
192 11.3% fell within the very large. This is higher HRQoL impact compared to studies conducted in other  
193 part of the world. A study done in Belo Horizonte, Brazil in 2009-2010 showed that among 20 CL patients  
194 70 % of them had a moderate/ large impact on their HRQoL [14]. Another study done in UK on returning  
195 travelers indicated that 63% among 46 adults reported moderate or higher impact on their quality of life  
196 [15]. The high proportion of our participants (270, 89.4%) having lesion in their head and neck regions,  
197 aesthetically important region, and the significantly poor HRQoL (P=0.018) observed in them might  
198 explain the large proportion of patients with high HRQoL effect.

199 The younger age group (20-49) had greater odds of having poor HRQoL compared to the 50 or above  
200 age group a finding that trend with a finding in Psoriasis patients [19]. Probably, for younger age group  
201 visible aesthetic damages might more crucial while attempting to enter or assume more social, or  
202 interpersonal relationship.

203 Despite the differences in sociocultural, study setting and causative species difference people are  
204 concerned with the level of aesthetic damage due to CL. The CL clinical phenotype were associated  
205 significantly with different DLQI scores. Individuals with DCL had 8.8 times higher odds having poor  
206 HRQoL compared to patients with LCL. Probably, patients feel the level of disfigurement. In line to our  
207 finding Refai et al., observed that in active LCL cases those with Plaque-ulcers type had higher DLQI  
208 score [20]. This is also consistent with studies conducted in Iran by Vares et al., which indicated that  
209 those with ulcerated lesions had lower quality of life compared to non-ulcerated [14].

210 We witnessed that the "Leisure" (P=0.002) and "Personal Relationship" (P=0.001) DLQI sub domain  
211 significantly correlated with male sex. This observation corroborates the previous explanations that the  
212 culturally assumed social status of males might probably made them more concerned of their HRQoL.  
213 Moreover, in a population based cohort study on schizophrenia, it was observed that Ethiopian women  
214 did not reported upfront on their overall life satisfaction or quality of spousal relationships [21].

215 The high CL related HRQoL impact in the "symptom and sign", and "work and School" DLQI sub domain  
216 and severe form of CL, DCL, trends with previous studies [14, 15]. The highest impact of CL in Vares et

217 al.,[14] study was in the “symptom and sign” sub domain while it was in the “work and School” in that of  
218 Toledo et al., [15]. Treatment appears to have a low effect perhaps the study participants were  
219 treatment naïve and were yet to experience the effect of treatment on their HRQoL.

220 This study showed that active CL holds important HRQoL burden on affected individuals. Thus, warrants  
221 improved, counseling on the nature of CL, therapeutic options as well as clinical outcomes and  
222 complications related to CL care and management. Importantly, patient-reported outcome measures  
223 including the DLQI should be used to assess the efficacy of treatments and patient care algorithms.

224

### 225 **Limitations of the study**

226 This study is a cross sectional prior to treatment, we cannot comment on possible treatment related  
227 changes in HRQoL. The clinical classification was based on the judgement of the dermatologist who  
228 assessed the patient rather than standardized case definitions.

229

### 230 **Funding**

231 This work was funded by Armauer Hansen Research Institute (Norad and Sida Core funding) to  
232 Endalamaw Gadisa.

### 233 **Acknowledgements**

234 We are grateful to the study participants for their time and the dermatologists and staff of the  
235 Dermatology Department. Dr Michael Marks participated in discussions concerning analysis. A special  
236 thank you to Edom Getachew who assisted with data entry.

237

### 238 **References**

239

- 240 1. WHO. Leishmaniasis 2022 [cited 2022 12/10/2022]. Cutaneous leishmaniasis].
- 241 2. Seid A, Gadisa E, Tsegaw T, Abera A, Teshome A, Mulugeta A, et al. Risk map for cutaneous  
242 leishmaniasis in Ethiopia based on environmental factors as revealed by geographical information  
243 systems and statistics. *Geospat Health*. 2014;8(2):377-87. doi: 10.4081/gh.2014.27. PubMed PMID:  
244 24893015.
- 245 3. Kuru T, Janusz N, Gadisa E, Gedamu L, Aseffa A. Leishmania aethiopia: development of specific  
246 and sensitive PCR diagnostic test. *Exp Parasitol*. 2011;128(4):391-5. doi: 10.1016/j.exppara.2011.05.006.  
247 PubMed PMID: 21616071.
- 248 4. Negera E, Gadisa E, Hussein J, Engers H, Kuru T, Gedamu L, et al. Treatment response of  
249 cutaneous leishmaniasis due to Leishmania aethiopia to cryotherapy and generic sodium  
250 stibogluconate from patients in Silti, Ethiopia. *Trans R Soc Trop Med Hyg*. 2012;106(8):496-503. doi:  
251 10.1016/j.trstmh.2012.02.006. PubMed PMID: 22503475.

- 252 5. Negera E, Gadisa E, Yamuah L, Engers H, Hussein J, Kuru T, et al. Outbreak of cutaneous  
253 leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. *Trans R*  
254 *Soc Trop Med Hyg.* 2008;102(9):883-90. doi: 10.1016/j.trstmh.2008.03.021. PubMed PMID: 18479722.
- 255 6. van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah AM, Diro E. Treatment of Cutaneous  
256 Leishmaniasis Caused by *Leishmania aethiopica*: A Systematic Review. *PLoS Negl Trop Dis.*  
257 2016;10(3):e0004495. Epub 20160303. doi: 10.1371/journal.pntd.0004495. PubMed PMID: 26938448;  
258 PubMed Central PMCID: PMC4777553.
- 259 7. Bsrat A, Berhe N, Balkew M, Yohannes M, Teklu T, Gadisa E, et al. Epidemiological study of  
260 cutaneous leishmaniasis in Saesie Tsaeda-embra district, eastern Tigray, northern Ethiopia. *Parasit*  
261 *Vectors.* 2015;8:149. Epub 20150307. doi: 10.1186/s13071-015-0758-9. PubMed PMID: 25889827;  
262 PubMed Central PMCID: PMC4359476.
- 263 8. van Henten S, Adriaensen W, Fikre H, Akuffo H, Diro E, Hailu A, et al. Cutaneous Leishmaniasis  
264 Due to *Leishmania aethiopica*. *EClinicalMedicine.* 2018;6:69-81. Epub 20190108. doi:  
265 10.1016/j.eclinm.2018.12.009. PubMed PMID: 31193672; PubMed Central PMCID: PMC6537575.
- 266 9. Ashford RW, Bray MA, Hutchinson MP, Bray RS. The epidemiology of cutaneous leishmaniasis in  
267 Ethiopia. *Trans R Soc Trop Med Hyg.* 1973;67(4):568-601. doi: 10.1016/0035-9203(73)90088-6. PubMed  
268 PMID: 4150462.
- 269 10. Boukthir A, Bettaieb J, Erber AC, Bouguerra H, Mallekh R, Naouar I, et al. Psycho-social impacts,  
270 experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and  
271 case management: An exploratory qualitative study in Tunisia. *PLoS One.* 2020;15(12):e0242494. Epub  
272 20201201. doi: 10.1371/journal.pone.0242494. PubMed PMID: 33259489; PubMed Central PMCID:  
273 PMC67707605.
- 274 11. Khatami A, Emmelin M, Talaei R, Miramin-Mohammadi A, Aghazadeh N, Firooz A, et al. Lived  
275 Experiences of Patients Suffering from Acute Old World Cutaneous Leishmaniasis: A Qualitative Content  
276 Analysis Study from Iran. *J Arthropod Borne Dis.* 2018;12(2):180-95. Epub 20180613. PubMed PMID:  
277 30123812; PubMed Central PMCID: PMC6091796.
- 278 12. Ooi XT, Choi E, Han H, Ahmad H, Patwardhan KR, Chandran NS. The psychosocial burden of  
279 hidradenitis suppurativa in Singapore. *JAAD Int.* 2023;10:89-94. Epub 20221207. doi:  
280 10.1016/j.jdin.2022.10.010. PubMed PMID: 36691658; PubMed Central PMCID: PMC9860399.
- 281 13. Bennis I, Belaid L, De Brouwere V, Filali H, Sahibi H, Boelaert M. "The mosquitoes that destroy  
282 your face". Social impact of Cutaneous Leishmaniasis in South-eastern Morocco, A qualitative study.  
283 *PLoS One.* 2017;12(12):e0189906. doi: 10.1371/journal.pone.0189906. PubMed PMID: 29261762;  
284 PubMed Central PMCID: PMC5738074.
- 285 14. Vares B, Mohseni M, Heshmatkhan A, Farzadeh S, Safizadeh H, Shamsi-Meymandi S, et al.  
286 Quality of life in patients with cutaneous leishmaniasis. *Arch Iran Med.* 2013;16(8):474-7. PubMed  
287 PMID: 23906253.
- 288 15. Toledo AC, Jr., da Silva RE, Carmo RF, Amaral TA, Luz ZM, Rabello A. Assessment of the quality of  
289 life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study. *Trans R*  
290 *Soc Trop Med Hyg.* 2013;107(5):335-6. Epub 20130308. doi: 10.1093/trstmh/trt021. PubMed PMID:  
291 23474473.
- 292 16. Peleva E, Walker SL. Cutaneous leishmaniasis and health-related quality of life in returning  
293 travellers to the UK. *J Travel Med.* 2020;27(7). doi: 10.1093/jtm/taaa188. PubMed PMID: 33145597;  
294 PubMed Central PMCID: PMC7883819.
- 295 17. Henok L, Davey G. Validation of the Dermatology Life Quality Index among patients with  
296 pododermatitis in southern Ethiopia. *Br J Dermatol.* 2008;159(4):903-6. Epub 20080730. doi:  
297 10.1111/j.1365-2133.2008.08773.x. PubMed PMID: 18671781.
- 298 18. Ranawaka RR, Weerakoon HS, de Silva SH. The quality of life of Sri Lankan patients with  
299 cutaneous leishmaniasis. *Mymensingh Med J.* 2014;23(2):345-51. PubMed PMID: 24858165.

- 300 19. Kwan Z, Bong YB, Tan LL, Lim SX, Yong ASW, Ch'ng CC, et al. Determinants of quality of life and  
301 psychological status in adults with psoriasis. *Arch Dermatol Res.* 2018;310(5):443-51. Epub 20180423.  
302 doi: 10.1007/s00403-018-1832-x. PubMed PMID: 29687328.
- 303 20. Refai WF, Madarasingha NP, Sumanasena B, Weerasingha S, Fernandopulle R, Karunaweera ND.  
304 Cutaneous leishmaniasis in Sri Lanka: effect on quality of life. *Int J Dermatol.* 2018;57(12):1442-6. Epub  
305 20180923. doi: 10.1111/ijd.14240. PubMed PMID: 30246447; PubMed Central PMCID:  
306 PMC6230306.
- 307 21. Mayston R, Kebede D, Fekadu A, Medhin G, Hanlon C, Alem A, et al. The effect of gender on the  
308 long-term course and outcome of schizophrenia in rural Ethiopia: a population-based cohort. *Soc  
309 Psychiatry Psychiatr Epidemiol.* 2020;55(12):1581-91. Epub 20200401. doi: 10.1007/s00127-020-01865-  
310 1. PubMed PMID: 32239264.
- 311 17. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into  
312 practice: What do dermatology life quality index scores mean? *J Invest Dermatol.* 2005 Oct;125(4):659-  
313 64. doi: 10.1111/j.0022-202X.2005.23621.x. PMID: 16185263.
- 314 19. Elsaie ML, Ibrahim SM. The effect of pulsed dye laser on cutaneous leishmaniasis and its impact on  
315 the Dermatology Life Quality Index. *J Cosmet Laser Ther.* 2018;20(3):152-5. Epub 20180309. doi:  
316 10.1080/14764172.2017.1343951. PubMed PMID: 28665162.